Carbapenem resistance associated with coliuria among outpatient and hospitalised urology patients

Adegoke, Anthony A.; Ikott, Winifred E.; Okoh, Anthony I.

doi:10.1016/j.nmni.2022.101019

Cited by 4 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, a significant decline in carbapenem resistance was observed across three bacterial species during the COVID-19 pandemic, with E. coli dropping by 1.2%, K. pneumoniae by 10.7%, and P. aeruginosa by 7.9% This contrasts with findings from other studies, such as Nordmann et al [ 38 ], Tacconelli et al [ 39 ], Adegoke et al [ 40 ], and Mares et al [ 41 ], which reported a global rise in carbapenem resistance, particularly in K. pneumoniae and P. aeruginosa . The research by Mares et al revealed significant changes in antibiotic resistance among Pseudomonas spp., particularly concerning carbapenems.…”

Section: Discussioncontrasting

confidence: 99%

Decline in ESBL Production and Carbapenem Resistance in Urinary Tract Infections among Key Bacterial Species during the COVID-19 Pandemic

Altamimi,

Binkhamis,

Alhumimidi

et al. 2024

Antibiotics

View full text Add to dashboard Cite

The COVID-19 pandemic has led to significant changes in healthcare practices, including increased antibiotic usage. This study aimed to investigate the impact of the pandemic on the prevalence of extended-spectrum β-lactamase (ESBL) production and carbapenem resistance among key bacterial species causing urinary tract infections (UTIs). Conducted at King Fahad Medical City in Riyadh from January 2018 to December 2022, the study analyzed urine samples from 9697 UTI patients. Patients were categorized into ‘pre-COVID-19’ and ‘during COVID-19’ groups. Bacterial isolates were identified, and antimicrobial susceptibility testing was performed following guidelines. ESBL production was detected using the Double-Disc Synergy Test. Escherichia coli and Klebsiella pneumoniae were the main pathogens. During the pandemic, ESBL production decreased in E. coli by 1.9% and in K. pneumoniae by 6.0%. Carbapenem resistance also declined, with E. coli displaying a 1.2% reduction and K. pneumoniae and Pseudomonas aeruginosa displaying 10.7% and 7.9% reductions, respectively. Notably, logistic regression analysis revealed that the odds of ESBL presence were 10% lower during the COVID-19 pandemic (OR 0.91; 95% CI 0.83–0.99; p = 0.040), and there was a significant reduction in the odds of carbapenem resistance (OR 0.43; 95% CI 0.37–0.51; p < 0.001). This study reveals a significant decrease in ESBL production and carbapenem resistance among UTI pathogens during the COVID-19 pandemic, hinting at the impact of modified antibiotic and healthcare approaches. It emphasizes the need for persistent antimicrobial resistance surveillance and policy adaptation to address resistance challenges, offering key directions for future public health actions.

show abstract